Treatment | CYP1A2 | CYP2C9 | CYP3A4 | ||||||
---|---|---|---|---|---|---|---|---|---|
Activity | -Fold Induction | Activity | -Fold Induction | Activity | -Fold Induction | ||||
CLE | |||||||||
0 μM | 4.7 ± 2.5 | 32 ± 16 | 36 ± 46 | ||||||
1 μM | 5.2 ± 2.1 | 1.2 ± 0.23 | 56 ± 39* | 2.0 ± 1.9 | 33 ± 41 | 0.95 ± 0.10 | |||
10 μM | 4.4 ± 3.1 | 0.86 ± 0.18 | 18 ± 10 | 0.57 ± 0.12 | 42 ± 52* | 1.2 ± 0.07 | |||
100 | 4.1 ± 2.6 | 0.82 ± 0.23 | 23 ± 15 | 0.67 ± 0.23 | 225 ± 235* | 7.3 ± 2.6 | |||
Positive controlsa | 135 ± 37* | 39 ± 30 | 177 ± 90* | 5.4 ± 0.21 | 1099 ± 414* | 77 ± 56 | |||
H152/81 | |||||||||
0 μM | 6.0 ± 3.3 | 33 ± 23 | 39 ± 49 | ||||||
1 μM | 6.1 ± 4.2 | 0.94 ± 0.43 | 31 ± 19 | 0.97 ± 0.11 | 39 ± 51 | 0.96 ± 0.037 | |||
10 μM | 5.5 ± 2.9 | 0.94 ± 0.042 | 18 ± 13* | 0.54 ± 0.18 | 50 ± 65 | 1.2 ± 0.22 | |||
100 μM | 5.0 ± 2.9 | 0.81 ± 0.21 | 23 ± 22* | 0.63 ± 0.29 | 294 ± 316* | 8.7 ± 5.0 | |||
Positive controls | 151 ± 28* | 34 ± 23 | 167 ± 128* | 4.9 ± 0.76 | 1235 ± 322* | 82 ± 60 |